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Summary 
Organization of the postsynaptic GA BA-receptor chloride channel complex on spinal cord neurons 
In this paper it is shown that the postsynaptic GABA-receptor chloride ion channel complex is composed 
of several functional subunits. There are probably at least two stereospecific locations on the receptor for 
GABA-binding and both must be occupied to obtain an increase in chloride conductance. The interaction 
between these sites is uncertain but there could be either positive cooperativity between the sites or only a 
requirement that both sites are occupied without occupation of either site affecting the affinity for GABA of 
the other site. There is a chloride conductance channel coupled to the GABA receptor which opens for an 
average of 20 msec and has an average conductance of 18 pS. The GABA-coupled chloride channel may or 
may not have the same composit ion as the glycine coupled chloride channel. 
In addition to the GABA-recognit ion site and the chloride ion channel, GABA-receptors must have 
additional binding sites or modulator  sites where drugs can bind to modify GABA activation of the 
GABA-receptor.  The convulsant P I C R O  binds to a site which is independent of the GABA-recognition site 
and PICRO reduces GABA responses. Barbiturates and benzodiazepines augment GABA-responses without 
reducing GABA-binding and thus they must bind to a modula tor  site independent of the GABA recognition 
site. Whether or not this is the same site as the P I C R O  binding site is uncertain. Thus, the GABA-receptor-  
chloride ion channel complex is composed of at least: 1) two GABA-binding sites; 2) a chloride ion channel; 
3) a eonvulsant binding site (PICRO-binding  site) and 4) an anticonvulsant binding site. This organization 
serves several obvious purposes. First, since two GABA-molecules are required to activate GABA-coupled 
chloride ion channels, the dose-response relationship for GABA is sigmoidal and steep. Thus minor shifts in 
GABA affinity will produce large alterations in GABA-responses and the GABA receptor can be easily 
modulated. Second, since the receptor has binding sites for convulsant and anticonvulsant compounds which 
decrease and increase GABA-responses, GABAergic inhibition can easily be modulated. 
Introduction 
The neutral amino acid 7-aminobutyric  acid 
(GABA) was initially identified in brain in 1950 
(1, 2, 3). Four years later Hayashi (4) suggested 
that GABA might play a role in the regulation of 
neuronal excitability and Florey (5) discovered that 
an extract of mammalian brain had an inhibitory 
action on crayfish stretch receptor neurons. When 
the active component  of the brain extract was 
identified as GABA, Florey and his colleagues (61) 
suggested that GABA might be an inhibitory 
neurotransmitter  in the mammalian central nervous 
system (CNS). The inhibitory action of GABA on 
mammal ian  CNS neurons was demonstrated by 
Curtis and coworkers (7) in 1959 using iontophoresi,; 
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of GABA and other amino acids f rom multibarrel 
micropipettes. While GABA strongly inhibited 
firing of spinal cord neurons, they concluded that 
GABA was not the major  inhibitory neurotrans- 
mitter in spinal cord. In a later study, Curtis and 
coworkers (8) demonstrated that GABA produced 
hyperpolarization and increased conductance and 
that the GABA-responses had a reversal potential 
similar to that of inhibitory postsynaptic potentials 
recorded in spinal cord. It is now well accepted that 
GABA is a major inhibitory neurotransmitter 
throughout  the CNS (9-12) and modification of 
GABAergic inhibition has been determined to be 
involved in the actions of a number  of drugs used 
clinically such as barbiturates (13-18) and 
benzodiazepines (13, 18 24) and in certain disease 
states such as epilepsy (25) and Huntington's 
Disease (26-28). 
The purpose of the present article is to review the 
pharmacology of GABA-mediated inhibition in the 
spinal cord both in vivo and in primary dissociated 
cell culture. In addition, we will review the 
pharmacology of several drugs which have actions 
on GABAergic synaptic transmission with partic- 
ular emphasis on convulsants, anticonvulsants and 
anesthetics. While it has been possible to gain much 
information from studies of spinal cord neurons in 
vivo, considerable technical advantage for investi- 
gation of GABA-mediated inhibition can be 
obtained by growing spinal cord neurons in pr imary 
dissociated cell culture. Therefore, we will review: 
1) the technique of dissociated cell culture and the 
properties of spinal cord and dorsal root ganglion 
neurons in cell culture; 2) the metabolism, uptake, 
binding, and release of GABA and the action of 
drugs acting on these systems; 3) the physiology of 
GABA in both in vivo and in vitro preparations; 
and 4) the actions of convulsant, anticonvulsant 
and anesthetic drugs which antagonize or enhance 
GABA-responses and the releationship between 
their actions on GABA-responses and their physi- 
ological and pharmacological effects. 
Mammalian spinal cord neurons in primary- 
dissociated cell culture 
Mammal ian  spinal cord (SC) and dorsal root 
ganglion (DRG) neurons can be grown and main- 
tained in pr imary dissocN~'ted cell culture. Cultures 
Fig. 1. Spinal cord neuron in primary dissociated cell culture. 
The large spinal cord neuron is multipolar with four large 
dendrites (Den) emerging from the soma and a single axon 
having its origin from a proximal segment of one of the 
dendrites. Magnification is )<225. (From Ref. (202)). 
are prepared from spinal cord and attached dorsal 
root ganglia obtained from fetal animals using the 
methods developed by Fischbach (29) and Nelson 
(30). SC-DRG neuronal cocultures derived from 
fetal mice contain both SC and D R G  neurons 
which can be unambiguously identified using 
morphological and electrophysiological criteria 
(30). 
Large SC neurons (>20 #M diameter somata) 
are multipolar with several dendrites emerging 
from their somata (Fig. 1). Dendrites are covered 
with synaptic terminals over most of their mem- 
brane surface. A single axon usually emerges f rom 
the soma or from a proximal dendritic site and 
makes numerous synaptic contacts with other SC 
neurons (31). D R G  neurons are round, contain 
sharply defined nuclei and nucleoli and are usually 
unipolar or bipolar. D R G  neurons receive no 
synaptic input but D R G  axons make synaptic 
contacts on SC neurons. 
Electrophysiological properties of SC and D R G  
neurons in cell culture are similar to those of 
neurons in vivo (30). SC neurons display consider- 
able spontaneous synaptic activity and depolariza- 
tion evokes overshooting sodium-dependent action 
potentials. DRG neurons do not have spontaneous 




I sec • G L Y  
lOmV ~ 
Fig. 2. Spinal cord neurons in cell culture respond to GABA (30 
hA), fl-alanine (BALA) (60 nA) and glycine (GLY) (30 hA) with 
a membrane hyperpolarization and to glutamate (GLU) (40 hA) 
with a depolarization. Amino acids were applied by ionto- 
phoresis for 100 msec. All responses were obtained from a single 
neuron and membrane potential varied from 40 to -44 inV. 
(From Ref. (36)). 
shooting action potentials dependent upon both 
sodium and calcium. 
Since neurons grow in a monolayer in primary 
dissociated cell culture, it is possible to obtain 
intracellular recordings under visual control from 
individual neurons, to apply neurotransmitters or 
drugs to selected somatic or dendritic locations 
using iontophoretic or pressure ejection techniques 
or to superfuse the culture with neurotransmitters 
or drugs. Individual neurons can also be penetrated 
by two independent micropipettes to apply the 
voltage clamp technique. 
Synaptic transmission between DRG and SC or 
between SC and SC neurons can be studied by 
simultaneously recording from neuron pairs 
(31-33). Excitatory and inhibitory postsynaptic 
potentials can be evoked from SC neurons while 
only excitatory postsynaptic potentials have been 
evoked by DRG stimulation. 
The postsynaptic amino acid pharmacology of 
SC neurons has been well characterized (34-36). 
The majority of SC neurons (>90%) respond to 
iontophoretically applied inhibitory neutral amino 
acids (GABA, fl-alanine, glycine) and to the 
excitatory acidic amino acid glutamic acid (Fig. 2). 
Thus SC and DRG neurons in primary disso- 
ciated cell culture have been demonstrated to have 
typical differentiated neuronal morphology, rich 
synaptic connectivity and extensive amino acid 
sensitivity and provide an excellent preparation for 
study of the physiology and pharmacology of SC 
and DRG neurons in vivo. 
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GABA metabolism 
GABA has a unique regional distribution in the 
nervous system as does the enzyme responsible fi~r 
its synthesis, L-glutamic acid decarboxylase (GAD) 
(37). Levels are highest in substantia nigra and 
lowest in brainstem and spinal cord. Within spinal 
cord, GABA levels are highest in the dorsal and 
dorsolateral part of dorsal horn (38). The synthesis 
and degradation of GABA is similar throughout 
the nervous system. 
The immediate precursor for GABA is L-glutamic 
acid. The formation of GABA from glutamate was 
described in the first papers reporting the discovery 
of GABA in CNS tissues (1, 2, 3). L-Glutamate is 
derived principally from glutamine and a- 
ketoglutarate, the latter originating from the 
tricarboxylic acid cycle and glucose. However, 
alternative pathways have been described and vari- 
ous metabolic compartments of both glutamate 
and GABA exist (39). GAD (E.C.4.1.1.15) is the 
enzyme which catalyzes the formation of GABA 
from glutamate. GAD has a molecular weight of 
85 000 daltons and requires pyridoxal phosphate 
(40). The enzyme is cytoplasmic and is the rate- 
limiting enzyme in GABA synthesis. It is concen- 
trated in the terminals of GABAergic neurons. The 
enzyme has been purified, antibodies raised against 
it and the immunocytochemicallocalization studied 
in CNS (41-43). In spinal cord, GAD-positive 
terminals are concentrated in Rexeds laminae I, II 
and Ill  and axo-axonic, axodendritic and 
axosomatic terminals have been demonstrated. All 
three types of connections are also seen in ventral 
horn and deep layers of dorsal horn (41-43). 
There are a variety of agents that interfere wit]h 
GAD activity either directly or as antagonists of 
pyridoxal phosphate. Antagonists of pyridoxal 
phosphate are primarily carbonyl trapping agents 
such as isoniazid and thiosemicarbazide. These 
agents not only inhibit GAD but also GABA- 
transaminase (GABA-T) (this enzyme is responsible 
for GABA degradation and also requires pyrid0xal 
phosphate). Depending on which enzyme is 
inhibited preferentially, GABA levels can be raised 
or lowered by these agents. Direct inhibitors of 
GAD, such as 3-mercaptoproprionic acid land 
allylglycine, are convulsants whose actions appear 
directly correlated with their abilities to reduce 
GABA levels (44-46). 
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GABA is degraded by the enzyme 4- 
aminobutyrate: 2-oxoglutarate aminotransferase 
(E.C.2.6.1.19) (GABA-T). The reaction is the 
transamination of t~-ketoglutarate with GABA to 
form glutamate and succinic semialdehyde. The 
enzyme (47) is localized to mitochondria and, like 
GAD, requires pyridoxal phosphate (48). The 
molecular weight of GABA-T is 109 000 daltons, 
the K m for GABA is 1.1 mM and 0.25 mM for 
~-ketoglutarate (40). The enzyme makes one mole- 
cule of glutamate for every molecule of GABA 
destroyed, thus continually replenishing the 
precursor supply for GABA. The enzyme has been 
purified and antibodies raised against it (41-43, 49). 
Distribution studies have shown the enzyme asso- 
ciated with the mitochondria of synaptic terminals, 
glia and postsynaptic neuronal regions. Carbonyl 
trapping agents inhibit GABA-T by interferring 
with pyridoxal phosphate. One of these is amino- 
oxyacetic acid (AOAA) which has been shown to act 
preferentially on GABA-T, raising GABA levels at 
low doses but causing convulsions at higher doses 
(secondary to inhibitory of GAD). Recently, several 
irreversible inhibitors of GABA-T have been 
described and promoted as possible anticonvulsants 
(50-53). The two agents studied most extensively 
have been ",/-acetylenic GABA (4-amino-hex-5- 
ynoic acid) and "/-vinyl GABA (4-amino-hex-5- 
enoic acid). These agents cross the blood brain 
barrier and thus could be used clinically. 
Unfortunately, at high doses these drugs also effect 
GAD and perhaps several other enzymes as well 
(50, 51, 53). A very potent GABA-T inhibitor, 
gabaculline ((-)-5-amino-l, 4-cyclohexadienyl car- 
boxylic acid); has a Ki_of approximately 1 #M for 
GABA-T and is only weakly inhibitory on GAD 
(54). 
The last enzyme in GABA degradation is succinic 
semialdehyde dehydrogenase (E.C. 1.2.1.24) 
(SSADH).  This enzyme is associated with mito- 
chondria and is distributed similarly to GABA-T 
(48, 55). The reaction converts succinic semi- 
aldehyde to succinic acid which enters the tricar- 
boxylic acid cycle (56). Valproic acid (sodium n- 
dipropylacetic acid), which has been found useful 
as an anticonvulsant in humans, produced a dose 
dependent increase in GABA levels in animals. The 
agent was originally thought to be an anticon- 
vulsant secondary to inhibition of GABA-T (57) 
but more recently it has been shown to be a more 
potent inhibitor of SSADH (58) and more 
importantly to directly augment GABA responses 
recorded electrophysiologically(59). We have found 
that valproic acid is a weak inhibitor of GAD, 
GABA-T and SSADH (ICs0's greater than 15 mM 
for all three enzymes) in mouse brain and spinal 
cord neurons in dissociated cell culture. The doses 
needed to cause 50% inhibition were much above 
that necessary for anticonvulsant effects (60). 
GABA uptake 
GABA is actively accumulated into nervous 
tissues by both high and low affinity transport 
systems (61, 62). The high affinity uptake is satur- 
able, temperature-sensitive and sodium- and 
energy-dependent. High affinity uptake has been 
selectively evaluated by incubating small tissue 
slices or brain homogenates with low concentra- 
tions (10 -5 to 10 -8 M) of radioactively labeled 
GABA for short time periods (less than 10 rain) 
(63, 64). Under these conditions little GABA is 
metabolized. The high affinity uptake system has a 
K m of 5-40 ~M depending on the preparation (64). 
In nervous tissue, it is felt that uptake occurs 
primarily into GABAergic nerve terminals. It has 
even been possible to show GABA uptake into 
specific populations of synaptosomes by sucrose 
gradient centrifugation (65). Nevertheless, there are 
several studies which indicate that high affinity 
uptake systems are also present on glial cells in 
certain tissues such as rat sensory ganglia and 
cultured rat glial tumor cells (66-69). There is also 
controversy over whether GABA uptake actually 
functions as a mechanism for GABA inactivation. 
There is evidence that the apparent uptake is really 
a net exchange. A variety of conflicting studies exist 
on GABA uptake and the functions of the various 
transport  systems have yet to be resolved 
(68, 70-73). 
Autoradiographic techniques have been the most 
reliable way of determining which tissue elements 
accumulate GABA. In brain, the percentage of 
nerve terminals labeled by 3H-GABA has a regional 
distribution consistent with the predicted distribu- 
tion of GABAergic terminals (74, 75). In spinal 
cord homogenates, it has been demonstrated that 
approximately 25% of synaptic terminals were 
labeled when incubated with either 3H-GABA or 
3H-glycine alone (74). When incubated with both 
labeled amino acids together, approximately 50% 
of the terminals were labeled, suggesting that the 
two amino acids were accumulated into separate 
populations of terminals. More recently, lesions of 
specific brain regions or pathways have been shown 
to selectively decrease GABA uptake in the projec- 
tion areas of these pathways (63, 70, 76). Thus, 
measurement of GABA uptake is a valuable tech- 
nique in the mapping of GABAergic pathways. 
GABA uptake has been studied in organ culture 
and dissociated cell culture of nervous tissue 
(77-79). In spinal cord cultures, a great number of 
neurons and almost all glial cells were labeled after 
incubation with 3H-GABA. In cerebellar cultures, 
glia, interneurons and Purkinje cells accumulated 
GABA. In dorsal root ganglia cultures, neurons 
were labeled only if they had been stripped of glial 
elements, otherwise only satelite glial cells were 
labeled (77). 
In dissociated cell cultures of embryonic chick 
spinal cord, GABA uptake has been studied chem- 
ically and by autoradiography (79). Both high and 
low affinity systems were observed with Kms of 4 
and 100 #M respectively. The high affinity system 
was temperature-sensitive, saturable and sodium- 
dependent and inhibited more potently by 2,4- 
diaminobutyric acid than /3-alanine. Autoradio- 
graphy demonstrated uptake into about one half 
the multipolar neurons and an absence of uptake 
into glia and nonneuronal cell types. 
Blockers of the GABA transport system have 
been studied rather extensively (80-82). 2,4- 
Diaminobutyric acid (DABA) and nipecotic acid 
have been found to be more potent in inhibiting 
uptake into nerve terminals and neurons than fl- 
alanine (83). Recently, +-cis-3-aminocyclohexane- 
carboxylic acid has been found to be a more 
selective inhibitor of neuronal uptake than DABA 
or nipecotic acid (84). Of all the uptake blockers 
that have been studied, the most potent are R- 
nipecotic acid (IC50 = 8/~M), and cis-4-hydroxy- 
nipecotic acid (ICs0 = 12 #M) (85). The active 
molecular conformations for inhibition of neuronal 
GABA uptake differ somewhat from the confor- 
mations for optimal inhibition of glial uptake 
(86, 8"1). Furthermore, structure activity studies 
indicate that the conformation of GABA that 
interacts with the transport system is quite different 
from that which interacts with GABA synaptic 
receptors. 
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Inhibitors of GABA uptake may enhance the 
neurophysiologic depressant effects of GAlqA 
(88, 89). However, they do not cross the blood 
brain barrier. Ethyl esters of nipecotic acid cross 
into brain and protect against pentylenetetrazole 
seizure but their pharmacologic effectiveness in 
humans is unknown (85). 
GABA release 
The release of GABA from superfused tissues, 
glial cells, brain and spinal cord slices and 
synaptosomes has been studied extensively in recent 
years (90-96). There have been, however, conflicting 
data as to whether the release is calcium-dependent 
and whether certain forms of stimulation (i.e. 
electrical, potassium or veratradine) are better than 
others. Potassium evoked release of exogenously 
labelled GABA has been demonstrated to be cal- 
cium dependent in brain slices and synaptos0mes 
(92, 93, 95, 97, 99, 101). Electrical or veratradine 
induced release of GABA was less consistently 
calcium-dependent (97, 99, 102). In culture sys- 
tems, potassium-evoked release of exogenously 
labeled 3H-GABA has been demonstrated and 
release was inhibited by reducing the extracellular 
Ca++/Mg ++ ratio (78). The pharmacology af the 
GABA release was not investigated in culture. In 
mouse neurons in dissociated cell culture, we found 
that exogenously labelled GABA was released by 
high-potassium and also was dependent or~ the 
Ca++/Mg ++ ratio. The release was. inhibited b,y 
GABA but not by DABA, fl-alanine, muscimol, 
barbiturates or bicuculline. Glial preparations have 
been found to accumulate GABA (see previous 
section) and to release GABA after potassium 
stimulation (96, 103, I04, 105). However, glial 
release did not appear to be calcium dependent 
(96, 105). 
Release of GABA and other neurotransmitters 
may be regulated by presynaptic GABA receptors 
(106-109). The calcium-dependent potassium- 
evoked release of GABA from substantia nigra was 
inhibited by both GABA and muscimol; however, 
bicuculline also inhibited the release and additional 
pharmacology was not reported (108). Recently, 
GABA has been shown to facilitate the release of 
3H-dopamine from caudate nucleus (106, 107) but 
the effect was not antagonized by bicuculline nor 
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picrotoxin, and others have found an inhibition of 
3H-dopamine release from striatal slices by GABA 
(109). The discrepancies in the results as to whether 
GABA facilitates or inhibits release may be secon- 
dary to technical differences in experimental 
methodology. It does appear clear, however, that 
the pharmacology of these presynaptic receptors 
may be quite different from that of postsynaptic 
receptors (106-109). 
GABA binding 
The electrophysiological effects of GABA on 
neuronal membrane properties have been studied 
extensively, and it has also been possible to study 
GABA receptors bi0chemieally by binding studies 
(110-114). The correlation of biochemical and 
neurophysiological data hopefully will allow a 
better understanding of the GABA receptor com- 
plex. Most binding studies to date have been 
performed in different preparations than the physi- 
ological studies making comparisons difficult. 
Mammalian neurons in primary dissociated cell 
culture provide a single system in which biochem- 
ical data and physiological data can be directly 
compared (115-118). 
A variety of ligands have been used to probe the 
properties of the GABA receptor complex. The two 
commonly used agonists are 3H-GABA and 3H- 
muscimol. 3H-GABA binds saturably to synaptic 
membranes and binding has a pharmacology and a 
subcellular and regional distribution consistent 
with that of the synaptic GABA receptor. Two 
binding sites can be discerned in nervous tissue, a 
low and a high affinity site with KDS of about 20 nM 
to about 200 nM, respectively (119). 
In initial studies of GABA binding, two condi- 
tions for binding were demonstrated (I 10, 120). If 
nervous tissue membranes were freshly prepared 
and incubated with 3H-GABA in the presence of 
sodium, then binding was no t  bicuculline sensitive 
and had a pharmacology similar to the uptake site 
(so-called sodium-dependent binding). If mem- 
branes were frozen and assayed for binding in the 
absence of sodium, binding was bicuculline sensi- 
tive and had a pharmacology consistent with the 
synaptic receptor (so-called sodium-independent 
binding). Initial studies of these sodium- 
independent sites suggested one population of 
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Fig. 3. Scatchard analysis of specific 3H-GABA binding to adult 
rat spinal cord membranes.  Membranes  from whole spinal cord 
homogenized in 50 mM Tris-citrate buffer, pH 7.1 at 4 ° C were 
incubated at 37 ° C for 30 min with 0.05% Triton X-100 (v/v) and 
then centrifuged at 48 000 )< g for 10 min. The membranes  were 
washed 3 times with fresh ice cold buffer and finally resuspended 
in buffer. Aliquots of the suspension (0.2-0.8 mg protein) were 
incubated in triplicate with increasing concentrations of 3H- 
GABA (1-500 nM) at 4 ° C for 20 rain. The assay was terminated 
by filtration over Wha tman  GF/B glass fiber filters. Specific 
binding (e) was obtained by subtracting from the total 3H- 
GABA bound,  that bound in the presence of 0.1 mM GABA 
(run in triplicate). The experiment  has been repeated four times. 
binding sites. Subsequent studies, however, 
demonstrated that two sites became apparent if the 
tissue was pretreated with the detergent Triton X- 
100 or if the membranes were repeatedly frozen and 
thawed and then washed extensively (119). 
Furthermore, this procedure increased the affinity 
of GABA for its receptor by at least one order of 
magnitude. It occurred to several investigators that 
this phenomenon might represent the removal of an 
endogenous GABA receptor modulator from the 
neuronal membranes (GABA-modulin) (121-123). 
Some of the 'modulator '  may be GABA itself but a 
relatively small protein or peptide has also been 
implicated. The distribution of the high affinity 
sites varied quite dramatically throughout the CNS. 
The number of high affinity sites was highest in the 
cerebellum and lowest in the spinal cord (124, 125). 
In our laboratory we have studied 3H-GABA 
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Fig. 4. Scatchard analysis of specific 3H-muscimol binding to 
adult  rat spinal cord membranes.  The assay was identica ! to that 
described for 3H-GABA in Fig. 3, however, 3H-muscimol was 
the labeled ligand. The experiment has been replicated four 
times. 
binding in spinal cord and only low affinity sites 
(K D = 340 nM; Bmax = 9.8 pmol /mg prot) could be 
demonstrated (Fig. 3) whereas in brain the identical 
technique indicated two sites (low affinity K D --- 210 
nM, Bma x = 10.1 pmol /mg prot, and high affinity 
KI9 = 20 nM, Bma x = 1.5 pro•l /rag prot). 
3H-Muscimol also binds to central nervous 
GABA receptors but only to the high affinity site in 
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Fig. 5. Scatchard analysis of specific 3H-GABA binding to 
membranes  from mouse spinal cord neurons in dissociated cell 
culture prepared as described in Fig. 3 except that 0.025% Triton 
X-100 was used and two washes were carried out and the 
membranes  centrifuged for 20 rain at 48 000 X g. The results are 
the combined data from two experiments and the experiment 
has been replicated four times. 
brain, the K D for 3H-muscimol binding was 6 nM 
and the Bma x was 1.7 pmol/mg prot which was 
similar to the Bma x of the high affinity GABA 
receptor binding site. When we studied 3][-[_ 
muscimol in tritonized spinal cord membranes, 
only one binding site was found with a K D = 6 nM 
and Bma x = 0.24 pmol /mg protein (Fig. 4). The 
ratio therefore of high to low affinity sites in spinal 
cord was 1:40. Such a ratio precluded accurate 
quantitation of the high affinity site in spinal cord 
using 3H-GABA. Even in routine assays at very low 
concentrations of 3H-GABA, the relative contribu- 
tion of the low affinity site was substantial. 
The high affinity GABA and muscimol binding 
sites are considered to be associated with t]he 
postsynaptic complex (129). Lesions of various 
nuclei receiving GABAergic input lead to a loss of 
high affinity receptor sites (129). Also, the  high 
affinity receptor sites are the ones that increased 
during the development of supersensitivity. In 
spinal cord in cell culture, we found two binding 
sites for GABA (Fig. 5) and only a high affinity site 
for muscimol. The KDS for the two GABA binding 
sites were similar to those found in rat brain and 
spinal cord although the ratio of high to low affinity 
sites was higher than that of rat spinal cordl The 
location of the low affinity sites have not been 
studied and their significance is unknown. 
The pharmacology of the high affinity site 
revealed that various receptor agonists (as judged 
by neurophysiological criteria) competed for 3H- 
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Fig. 6. Scatchard analyses of 3H-muscimol binding in adult rat 
spinal cord membranes  alone (e) and in the presence of 50 #M 
bicuculline (D). The assay is identical to that in Fig. 3. The 
experiment has been replicated four times. 
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GABA binding (130-133). Muscimol, 3-amino- 
propanesulphonic acid and dihydromuscimol are 
three potent receptor agonists. Structure activity 
studies have shown a specific optimal conformation 
of GABA for interaction with its receptor, different 
from the conformations which interact with the 
uptake sites, GAD and GABA-T (134, 135). 
Very few GABA antagonists inhibit GABA bind- 
ing. (+)-Bicuculline is the most potent antagonist 
with an IC50 = 5 # M (134). Other convulsant agents 
have been investigated and the only ones 
approaching (+)-bicuculline in potency were (+)- 
adlumidine, n-propylbicyclophosphate and n- 
butylbicyclophosphate (136). Bicuculline appeared 
to be a competitive inhibitor or GABA both by 
physiological criteria and by biochemical studies 
(Fig. 6) (136, 137). As indicated earlier, the affinity 
of GABA receptors could be enhanced dramati- 
cally by pretreating membrane fractions with Triton 
X-100 or by repeated freezing and thawing of the 
membranes with subsequent extensive washing 
(119). Such treatment of membranes, however, did 
not influence the Kifor bicuculline which is difficult 
to explain if it was indeed interacting strictly 
competitively with GABA at the receptor site. 
Furthermore, various anions enhanced the effec- 
tiveness of bicuculline in inhibiting GABA binding 
without changing the affinity of GABA itself (116). 
Although analysis of the effect of bicuculline on 
GABA dose response curves indicated competitive 
inhibition, such studies must be considered care- 
fully. It is possible for a substance to exhibit linear 
competitive inhibition and nevertheless bind to a 
site separate from (but closely linked to) the site for 
the natural substrate (138). 
A variety of other agents that antagonized or 
enhanced GABA responses in physiological exper- 
iments had no effect on GABA binding (110, 
112, 113). These included picrotoxinin, pentylene- 
tetrazole, penicillin, barbiturates and the benzo- 
diazepines. It is therefore unlikely that these drugs 
interact directly with the GABA recognition site 
but rather with a closely related site such as the 
chloride channel. Several of these agents have been 
labeled and binding to synaptic membranes studied 
(139-141). Several studies using 3H-bicuculline 
methiodide have been published but this agent was 
not very stable, was difficult to prepare and few 
detailed studies have been possible. 3H-Dihydro- 
picrotoxinin binding has been reported. Binding 
was not displaced by GABA and was weakly 
displaced by bicuculline (142). However, binding 
was displaced by picrotoxin analogues, barbiturates 
and the so-called cage convulsants in potencies 
similar to their clinical potencies. Finally, benzo- 
diazepine binding studies have demonstrated a 
class of benzodiazepine receptors intimately related 
to GABA receptors (143 146). GABA enhanced 
binding to benzodiazepine receptors as did a variety 
of GABA analogs. Anions also enhanced benzo- 
diazepine binding suggesting that there may be an 
association of the receptor with the chloride channel 
together in the same fractions (145, 147). Diazepam 
has also been found to interact with GABA modulin 
and thereby increase the affinity of GABA binding. 
The GABA receptor and the benzodiazepine 
receptor can be solubilized together (148, 149). 
The GABA receptor complex is certainly far 
from being completely understood. However, 
multiple probes are now available to do quite 
detailed studies on various receptor components 
and their interactions. 
GABA-mediated inhibition in the mammalian 
spinal cord 
In the mammalian spinal cord GABAergic inter- 
neurons are presumed to bave at least two different 
sites of action. Release of GABA onto primary 
afferent terminals would produce presynaptic inhi- 
bition while release onto somatic and dendritic 
locations would produce postsynaptic inhibition. 
Stimulation of primary afferents to the spinal 
cord produced a prolonged depolarization of 
primary afferent fibers (primary afferent depolari- 
zation (PAD)) (150, 151). PAD was associated 
with reduction of monosynaptic EPSPs recorded in 
anterior horn cells following orthodromic volleys in 
muscle and cutaneous afferents and was thought to 
be due to decreased release of transmitter from the 
primary afferent terminals. Eccles and coworkers 
(152) suggested that the reduction in transmitter 
release was due to release of transmitter from 
axoaxonic synapses located on the synaptic ter- 
minals of primary afferent fibers and also that the 
neurotransmitter involved might be GABA (153). 
Application of GABA to isolated spinal cord 
produced depolarization of dorsal root fibers 
(154-157) and GABA depolarized dorsal root 
ganglion cells (158-161). These actions of GABA 
were blocked by the GABA antagonists picrotoxin 
and bicuculline (157 161). Thus while GABA did 
alter membrane potential of primary afferent ter- 
minals it produced depolarization rather than the 
usual hyperpolarization associated with inhibition. 
Nonetheless, using immunohistochemical tech- 
niques Roberts and his colleagues (41-43) demon- 
strated that GAD-positive (and thus presumably 
GABAergic) axoaxonic contacts were made on 
primary afferent terminals. Based on ion substitu- 
tion experiments, blockade of chloride channels 
and intracellular recording from dorsal root gan- 
glion neurons it has been demonstrated that GABA 
increased chloride conductance and that depolari- 
zation was produced because the equilibrium 
potential for chloride ions was depolarized relative 
to resting membrane potential (159, 161, 162). 
Thus, there is physiological, pharmacological and 
anatomical evidence to support the notion that 
presynaptic inhibition in the dorsal horn is GABA- 
mediated. PAD, however, may have two different 
underlying mechanisms. The early picrotoxin- 
sensitive depolarization is probably due to release 
of GABA onto presynaptic terminals while the late 
phase is most likely a consequence of elevated 
interstitial potassium produced by the large afferent 
volley (163, 164). 
GABA-mediated postsynaptic inhibition is also 
probably present in the spinal cord. As discussed 
above, GABA levels are highest in the dorsal and 
dorsolateral portions of the dorsal horn (38). 
However, Roberts and his colleagues (41-43) have 
demonstrated GAD-positive terminals on both 
dorsal and ventral horn neurons. In the dorsal 
horn, GAD-positive terminals were identified on 
the somata of substantia gelatinosa neurons as well 
as the dendrites of Rexeds layer IV neurons. The 
lateral portion of the intermediate spinal gray 
matter and motor nuclei had a light concentration 
of GAD-positive material. Furthermore, most of 
the spinal cord neurons studied had at least some 
GAD-positive terminals on their somata and often 
on their dendrites. Thus there is immunocytochem- 
ical evidence for widespread distribution of 
GABAergic synaptic terminals. Consistent with 
this, spinal cord neurons were hyperpolarized by 
GABA (7-10, 165) and this hyperpolarization was 
due to an increase in membrane chloride conduc- 
tance (166). Despite these findings, much post- 
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synaptic inhibition in the spinal cord was 
strychnine-sensitive and bicuculline-insensitive 
implying that it was glycinergic (167). This includes 
short latency, strychnine-sensitive inhibition of 
motoneurons produced by single volleys in 
afferents from cutaneous and muscle nerves, inhi- 
bition of spinal interneurons and inhibition of 
firing of Renshaw cells produced by volleys in 
hindlimb cutaneous fibers (167-171). Nevertheless, 
while glycine may be the major neurotransmitter 
mediating postsynaptic inhibition in the spinal 
cord, there is substantial evidence that GABA- 
mediated postsynaptic inhibition is also present in 
the spinal cord. 
GABA-mediated postsynaptic inhibition in spinal 
cord neurons in cell culture 
Application of GABA onto SC neurons in cell 
culture using iontophoretic or pressure techniques 
produced both membrane potential and conduc- 
tance changes (34 36). During intracellular 
recordings with micropipettes containing 4M 
potassium acetate, GABA application produced 
membrane hyperpolarization and an increase in 
membrane conductance. GABA-response ampli- 
tude was a function of membrane potential, and the 
responses could be reversed by membrane byper- 
polarization. The average reversal potential for 
GABA-responses was -61.1 mV with an average 
resting membrane potential of 54.6 mV (35). The 
hyperpolarized reversal potential of GABA- 
responses associated with increased conductance 
suggested that either chloride and/or potassium 
conductance was involved in the response. The role 
of chloride conductance was examined by altering 
intra- and extracellular chloride concentrations 
and determining reversal potentials (35). Injection 
of chloride ions into SC neurons from intracel!ular 
recording micropipettes containing 3M KC1 
reduced the reversal potential of GABA-responses 
to -20.3 mV without altering resting membrane 
potential. Reduction of chloride ions from the 
bathing medium attenuated GABA-responses but 
addition of extracellular chloride from a large bore 
pipette restored the response. Thus, GABA- 
responses are chloride dependent. Similar experJ[- 
merits which increased extracellular potassium 
concentration did not alter the GABA-response 
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reversal potential ,,initially, but after sustained 
potassium induced ~ depolarization, the reversal 
potential was decreased~ This result s~uggested that 
potassium was not involved in GABA-responses 
and that the late changes in GABA-response reversal 
potential were due to redistribution of chloride ions 
induced by sustained depolarization. Thus, GABA- 
mediated inhibitory responses of SC neurons in cell 
culture are due to an increase in chloride conduc- 
tance. 
Sensitivity to GABA was not uniform over the 
surface of SC neurons (34, 35) with focal areas of 
increased sensitivity being distributed over the cell 
surface. Whether or not these 'hot spots' corre- 
spond to localized regions of subsynaptic GABA- 
receptors is uncertain. 
We have used the voltage clamp technique to 
study membrane currents induced by GABA (168). 
SC neurons were penetrated by two independent 
intracellular micropipettes. One micropipette 
recorded transmembrane potential and the other 
applied current. The voltage clamp apparatus held 
membrane potential by applying current through 
the current micropipette, and it was the applied 
current that was recorded. Under clamp conditions, 
the reversal potential for GABA-responses was 
8-10 mV more negative than resting membrane 
potential. We were able to obtain dose-response 
data during voltage clamp and demonstrate that 
when the log of the membrane current was plotted 
as a function of the log of the GABA iontophoretic 
current, a limiting slope averaged 1.5. This 
suggested that GABA interacts with the GABA-re- 
ceptor in a cooperative manner with at least two 
GABA molecules being required to activate the 
chloride conductance mechanism. 
Since the voltage clamp technique can be applied 
to SC neurons, conductance fluctuation (or 'noise') 
analysis can also be applied to investigation of 
GABA-mediated inhibition (173). Individual SC 
neurons were impaled with two independent 
micropipettes and GABA was applied by ionto- 
phoresis. Experiments had to be performed at 
26 ° C to reduce desensitization. The GABA induced 
increase in noise was analyzed using fluctuation 
analysis assuming that the noise derived was from 
statistical variation in the number of open ion 
channels activated by GABA with a mean level of 
open channels. Using this analysis, the average 
conductance of a single channel activated by GABA 
was 18 +_ 8.2 pS. Using spectral analysis of fluctu- 
ations during the plateau phase of the current 
responses, the average duration of the GABA 
channel open time was 20 + 6.6 msec. 
Thus, GABA inhibits SC neurons in primary 
dissociated cell culture by increasing chloride con- 
ductance and hyperpolarizing membrane potential. 
At least two molecules of GABA appear necessary 
to activate chloride channels. Activation of GABA- 
receptors briefly opens individual chloride channels 
with small unitary channel conductance. 
Antagonists of GABA-mediated inhibition 
The compounds bicuculline (BICUC), picr.otoxin 
(PICRO), pentylenetetrazol (PTZ) and penicillin 
(PCN) produce convulsions when applied to the 
mammalian CNS. The action of these agents on SC 
neurons in cell culture was investigated by applying 
GABA, other amino acids and convulsants by 
iontophoresis to focal areas of somata of SC 
neurons (174, 175). None of the convulsants altered 
membrane potential or input resistance but all four 
convulsants rapidly and reversibly antagonized 
GABA-responses (Fig. 7). The antagonism of 
. GABA-mediated inhibition was selective for GABA 
since responses to the amino acids /%alanine, 
glycine and glutamate were unaffected by convul- 
sant concentrations that antagonized GABA- 
responses. Using spinal cord neurons in cell culture, 
we have compared the antagonism of GABA- 
responses by BICUC with the displacement of 3H- 
GABA by BICUC. BICUC displaced high affinity 
3H-GABA binding with an EDs0 of 15/~M and an 
ED20 of 4 /~M (Young, Frere and Macdonald, 
unpublished work). Antagonism of GABA- 
responses was produced with an EDs0 of 1 ~zM and 
an EDI00 of 10 tzM. (Macdonald, Nowak and 
Young, unpublished work). Thus the physiologi- 
cally relevant displacement of binding occurred 
over 1 to 10 #M BICUC concentrations and high 
affinity binding was correlated with antagonism of 
postsynaptic GABA-responses. 
While all of these convulsants (PICRO, BICUC, 
PCN, PTZ) antagonized GABA-responses, their 
sites of action are uncertain. Since none of the 
convulsants antagonized glycine responses, which 
are also chloride-mediated, it is unlikely that they 
combine nonspecifically with all chloride channels. 
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Fig. 7. GABA-responses were antagonized reversibly by the 
convulsants picrotoxin (PICRO), bicuculline (BICUC), 
pentylenetetrazol (PTZ) and penicillin (PCN). GABA was 
applied by iontophoresis (50 msec. pulses) and intracellular 
recordings were made by glass micropipettes containing 3M 
KC1. Membrane potential was hyperpolarized to 80 to 90 mV 
and chloride ions were injected intracellularly. Thus GABA 
reversal potentials were depolarized to about -20 mV and the 
GABA-responses were depolarizing rather than hyperpolarizing. 
Calibration bars are 10 mV X 1 s. (From Ref. (175)). 
However, to antagonize GABA-responses each 
convulsant could combine: 1) with the active site of 
the GABA-receptor to competitively antagonize 
GABA-responses, 2) with the GABA-coupled 
chloride channel to non-competitively antagonize 
GABA-responses or 3) with a modulator site which 
either alters the affinity of the receptor for GABA, 
modifies the coupling between the receptor and 
chloride channel or changes chloride channel func- 
tion (decrease unitary channel open time or con- 
ductance). While adequate studies of the effect of 
GABA-antagonists on GABA dose-response curves 
on spinal cord neurons have not been published, 
some information is available from other prepara- 
tions. Much of the quantitative electrophysiolog- 
ical data has been obtained using lobster, crayfish 
and crab muscle since in these preparations intra- 
cellular penetrations Can be maintained for the 
extended time period required for acquisition of 
dose-response data. 
With intracellular recording techniques applied 
to invertebrate muscle fibers (176-178) and cat 
dorsal root ganglion neurons (161), BICUC antag- 
onized GABA-induced increases in conductance 
noncompetitively. Using extracellular recording 
from spinal cord interneurons in lamprey (179) and 
cuneate neurons (180, 181) BICUC antagonism 
was competitive. Using similar techniques, PICRO 
antagonized GABA-responses on invertebrate 
muscle fibers in a competitive (173), noncompeti- 
tive (182, 183) and mixed (178) fashion. PICRO 
antagonized GABA-responses competitively on 
invertebrate crayfish stretch receptor neurons (184) 
but noncompetitively on vertebrate dorsal root 
ganglion neurons (161), spinal cord interneurons 
(179) and cuneate neurons (180, 181). PCN antag- 
onized GABA-responses primarily noncompetJ[- 
tively in both invertebrate muscle fibers (185) and 
vertebrate cuneate neurons (186). Dose-response 
data for PTZ action on GABA-responses has not 
been published. In summary, BICUC, PICRO and 
PCN antagonize GABA-mediated inhibition in 
invertebrate muscle fibers and vertebrate dorsal 
root ganglion neurons noncompetitively. In studies 
of vertebrate central neurons PICRO and PCN are 
a lso noncompetitive antagonists but BICUC 
appears to be a competitive antagonist. From a 
technical point of view, the data from muscle fibers 
and dorsal root ganglion neurons was obtained 
usingintracellular recording while that from central 
neurons was either extracellular unit recordings or 
extracellular d.c. potentials. The intracellular data 
certainly more accurately reflects the actions of 
agonists and antagonists than does extracellular 
recording and therefore the data demonstrating 
noncompetitive antagonism is more likely to 
accurately reflect the interaction between convul- 
sants and GABA-responses. Thus, it is likely that in 
invertebrate muscle the convulsants act on a site 
other than the GABA-recognition site, either the 
GABA-coupled chloride channel or the coupling 
mechanism between the receptor and the channel. 
It is likely that these compounds produce con- 
vulsions by antagonizing GABA-mediated post- 
synaptic inhibition. Using the hippocampal slice 
preparation, Yamamoto (187) demonstrated that 
paroxysmal depolarizing shifts (PDS) can be 
recorded from CA3 pyramidal neurons following 
addition of the convulsant strychnine. PDS are the 
intracellular correlate of interictal 'spikes' recorded[ 
158 
in the scalp electroencephalogram of patients with 
epilepsy (188-190). The PDS are calcium- 
dependent depolarizations of dendritic origin ( 19 !) 
which are activated by orthodromic stimulation but 
do not invade the neuronal soma due to orthodromic 
disynaptic (presumably GABAergic) somatic inhi- 
bition (192). Antagonism of the inhibitory post- 
synaptic potentials by PCN, however, permits 
somatic invasion by the calcium-dependent 
depolarization and this results in PDS (193). PCN 
also produces spinal myoclonus in animals and 
man, presumbably also by blockade of GABA- 
mediated postsynaptic inhibition. Thus, it is likely 
that reduction of GABA-mediated inhibition may 
be involved in the pathogenesis of some forms of 
human epilepsy and spinal myoclonus. 
Augmentors of GABA-mediated inhibition 
Barbiturates, benzodiazepines and valproic acid 
are all used clinically as anticonvulsants. In addi- 
tion, barbiturates and benzodiazepines are 
employed therapeutically to reduce anxiety and 
facilitate sleep. Short acting barbiturates are also 
useful as anesthetics. The mechanisms of action of 
these compounds are uncertain but numerous pre- 
and postsynaptic actions have been described and 
many of these actions involve GABAergic trans- 
mission. Presynaptic actions of barbiturates 
include: 1) augmentation of GABA-mediated pre- 
synaptic inhibition (13, 16); 2) depression of evoked 
transmitter release from dorsal root afferents (194); 
3) augmentation of evoked transmitter release at 
the neuromuscular junction (195, 196); and 4) 
direct depolarization of dorsal root afferents which 
is blocked by the GABA antagonist picrotoxin (16). 
Postsynaptic effects of barbiturates include: 1) 
augmentation of GABA-mediated inhibition (15, 
17, 18); 2) antagonism of glutamate-mediated exci- 
tation (15, 18); 3) reduction of excitatory synaptic 
transmission; and 4) direct hyperpolarization of 
spinal cord motoneurons which is blocked by 
picrotoxin (15). 
Benzodiazepines have multipleactions including: 
1) augmentation of GABA-mediated presynaptic 
inhibition (19-21); 2) enhancement (197, 198) and 
antagonism (199, 200) of GABA-mediated post- 
synaptic inhibition; and 3) direct depolarization of 
sympathetic preganglionic nerve terminals (22). 
Valproic acid (VPA) has been shown to have a 
primarily presynaptic action to increase central 
nervous system GABA levels (57), by antagonizing 
the major GABA degradative enzymes including 
GABA-T (57) and, more importantly, SSADH (58). 
It was suggested that this enhancement of 
presynaptic GABA would increase GABA-me- 
diated inhibition. 
We have used mouse spinal cord neurons in 
primary dissociated cell culture to investigate the 
action of these compounds on postsynaptic GABA- 
responses, other amino acid responses and on 
resting membrane properties 
The anticonvulsant (phenobarbital (PhB) and 
mephobarbital (MB)) (Fig. 8) and sedative- 
anesthetic (pentobarbital (PB) and secobarbital 
(SB)) barbiturates (18, 201), the benzodiazepines 
(diazeparn (DZ) and chlordiazepoxide (CDZ)) (18, 
202) and valproic acid (57) all augmented GABA- 
responses without altering glycine responses. The 
mechanistic basis for this modulation of GABA- 
responses is uncertain but it is clear that, since these 
compounds augmented rather than antagonized 
GABA-responses, they did not compete with GABA 
for the GABA-binding site on the GABA receptor. 
We have proposed that they bind to a modulator 
site on the GABA-receptor chloride-channel com- 
plex to alter GABA-responses (201-203). Since 
barbiturates, benzodiazepines and valproic acid do 
not alter the affinity of saturable 3H-GABA binding 
to spinal cord or brain membranes, it is likely that 
these compounds do not bind to the GABA recog- 
nition site of GABA-receptors but instead bind to a 
separate site located on the GABA-receptor 
chloride-channel complex which alters either: 1) the 
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Fig. 8. GABA-responses were augmented by phenobarbital and 
pentobarbital. GABA was applied by iontophoresis (PhB: 
4,5 nA; PB: 3,2.5 nA) for 100 msec, recordings were made with 
micropipettes containing 3M KCI and membrane potential was 
hyperpolarized to -60 to 90 mV to achieve large depolarizing 
GABA-responses. (Macdonald & Schulz, unpublished work.) 
coupl ing between G A B A - b i n d i n g  and chloride 
channels  or 2) the GABA-coup led  chloride channel  
properties to increase uni tary  channel  conductance  
or open time. 
Barbiturates,  but  not  benzodiazepines  or valproic 
acid, also an tagonized  excitatory g lu tamate-  
responses (18, 203). For  PB and PhB, the two 
act ions occurred at the same drug concen t ra t ion  
with PB being somewhat  more potent  than  PhB. In  
addi t ion,  both PB and  PhB directly increased 
neurona l  chloride conduc tance  independent  of 
G A B A  (201, 203). This direct act ion of the barbi tu-  
rates was an tagonized  by the GABA-an tagon i s t s  
PCN and P I C R O ,  suggesting that the barbi tura tes  
were 'GABA-mime t i c . '  However,  as discussed 
above, barbi tura tes  have not  been demonst ra ted  to 
displace 3H-GABA from G A B A - b i n d i n g  sites and 
thus the available evidence suggests that  the barbi-  
turates  do not  bind directly to the G A B A - b i n d i n g  
site to increase chloride conduc tance  but  ra ther  
bind to an adjacent  site similar to that which 
P I C R O  binds. Thus barbi tura tes  could bind: 1) to 
the GABA-recep to r  chloride channel  complex and 
activate the GABA-coup led  chloride channel  
independen t  of the G A B A - b i n d i n g  site, 2) to an 
independent  ' ba rb i tu ra te  receptor '  which is also 
coupled to chloride channels  or 3) to the GABA-  
coupled chloride channel  with direct ac t ivat ion of 
the chloride channels.  
Despite having mult iple  actions,  it is likely that  
specific act ions of these compounds  are responsible 
for their clinical actions. A u g m e n t a t i o n  of GABA-  
mediated postsynapt ic  inh ib i t ion  is p robab ly  
responsible for the an t i convu l san t  actions of the 
barbi tuates  and  benzodiazepines  and possibly for 
va lp ro i c  acid. The  anes the t i c  ac t ions  of bar -  
bi turates are p robab ly  due to: 1) direct act ivat ion of 
chloride conductance ,  2) augmen ta t ion  of GABA -  
mediated inh ib i t ion  and  possibly an t agon i sm of 
g lu tamate -media ted  exci ta t ion and  3) reduct ion of 
presynapt ic  ca lc ium-entry  leading to a generalized 
d iminu t ion  of synapt ic  t ransmiss ion.  Thus,  the 
GABA-recep tor  chloride channel  complex is a 
major  site of act ion for the clinical act ions of these 
compounds .  
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